BD OneFlow LST; BD OneFlow B-CLPD T1; BD FACSLyric Flow Cytometer, 8-color [4-2-2], 10-color [4-3-3], 12-color (4-3-5)
Bd Biosciences · Decision date Oct 20, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-20 for 510(k) K260215, received 01/23/2026, covering BD OneFlow LST, BD OneFlow B-CLPD T1 and the BD FACSLyric Flow Cytometer in 8-color [4-2-2], 10-color [4-3-3] and 12-color (4-3-5) configurations. The applicant is BD Biosciences, Milpitas, CA. The device classification is Flow Cytometric Test System For Hematopoietic Neoplasms under 21 CFR 864.7010, product code PWD with subsequent code OYE, in the Hematology specialty with an Immunology review panel. SESE means clearance, not PMA approval.
The review document excerpt describes BD OneFlow LST as an aid in identifying hematologically abnormal mature NK-cell lineages in patients having or suspected of having such findings, and notes in vitro diagnostic use with Kaluza C data analysis software. The excerpt is truncated and does not state the full intended use, the B-CLPD T1 indication, or the basis for the equivalence determination. No summary or decision summary content was available in the retrieved material, so clinical performance data and any labeling limitations remain unknown.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Hematology
- Decision date
- Oct 20, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260215
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Bd Biosciences
- Product code
- PWD
- Decision code
- SESE
- Decision date
- Oct 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Flow Cytometric Test System For Hematopoietic Neoplasms.
- Applicant
- Bd Biosciences
- Product code
- PWD
- FDA device class
- 2
FDA decision timeline
K260215 received
Application receipt date recorded by FDA.
K260215 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bd Biosciences
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Milpitas, CA
Sources and methodology
- Original FDA record: K260215
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records